Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Cash & Equivalents (2016 - 2026)

Biomerica's Cash & Equivalents history spans 17 years, with the latest figure at $1.3 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $1.3 million for Q1 2026, down 56.31% from a year ago — trailing twelve months through Feb 2026 was $1.3 million (down 56.31% YoY), and the annual figure for FY2025 was $3.1 million, down 26.67%.
  • Cash & Equivalents for Q1 2026 was $1.3 million at Biomerica, down from $2.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $10.2 million in Q1 2022 to a low of $1.3 million in Q1 2026.
  • The 5-year median for Cash & Equivalents is $4.2 million (2024), against an average of $4.9 million.
  • The sharpest move saw Cash & Equivalents soared 92.96% in 2022, then tumbled 67.12% in 2023.
  • Year by year, Cash & Equivalents stood at $5.1 million in 2022, then skyrocketed by 40.81% to $7.1 million in 2023, then tumbled by 66.75% to $2.4 million in 2024, then grew by 7.21% to $2.5 million in 2025, then tumbled by 47.46% to $1.3 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.3 million, $2.5 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.